https://scholars.lib.ntu.edu.tw/handle/123456789/415786
標題: | Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection | 作者: | Chen C.-J. Yang Y.-H. Lin M.-H. Lee C.-P. Tsan Y.-T. Lai M.-N. HSIAO-YU YANG Ho W.-C. PAU-CHUNG CHEN The Health Data Analysis in Taiwan (hDATa) Research Group The Health Data Analysis in Taiwan (hDATa) Research Group |
公開日期: | 2018 | 出版社: | Wiley-Liss Inc. | 卷: | 143 | 期: | 7 | 起(迄)頁: | 1578-1587 | 來源出版物: | International Journal of Cancer | 摘要: | It was suspected that aristolochic acid-induced mutations may be associated with hepatitis B virus (HBV), playing an important role in liver carcinogenesis. The purpose of this study was to investigate the association between the use of Chinese herbs containing aristolochic acid and the risk of hepatocellular carcinoma (HCC) among HBV-infected patients. We conducted a retrospective, population-based, cohort study on patients older than 18 years who had a diagnosis of HBV infection between January 1, 1997 and December 31, 2010 and had visited traditional Chinese medicine clinics before one year before the diagnosis of HCC or the censor dates. A total of 802,642 HBV-infected patients were identified by using the National Health Insurance Research Database in Taiwan. The use of Chinese herbal products containing aristolochic acid was identified between 1997 and 2003. Each patient was individually tracked from 1997 to 2013 to identify incident cases of HCC since 1999. There were 33,982 HCCs during the follow-up period of 11,643,790 person-years and the overall incidence rate was 291.8 HCCs per 100,000 person-years. The adjusted hazard ratios (HRs) were 1.13 (95% confidence interval [CI], 1.11–1.16), 1.21 (95% CI, 1.13–1.29), 1.37 (95% CI, 1.24–1.50) and 1.61 (95% CI, 1.40–1.84) for estimated aristolochic acid of 1–250, 251–500, 501–1,000 and more than 1,000 mg, respectively, relative to no aristolochic acid exposure. Our study found a significant dose–response relationship between the consumption of aristolochic acid and HCC in patients with HBV infection, suggesting that aristolochic acid which may be associated with HBV plays an important role in the pathogenesis of HCC. ? 2018 UICC |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046535837&doi=10.1002%2fijc.31544&partnerID=40&md5=8258e0cdfa346a369551e145c92da794 https://scholars.lib.ntu.edu.tw/handle/123456789/415786 |
ISSN: | 207136 | DOI: | 10.1002/ijc.31544 | SDG/關鍵字: | aristolochic acid; aristolochic acid; adult; Article; cancer diagnosis; cancer risk; Chinese medicine; cohort analysis; controlled study; disease association; drug use; exposure; female; follow up; hepatitis B; herbal medicine; human; incidence; liver cell carcinoma; major clinical study; male; middle aged; national health insurance; pathogenesis; priority journal; retrospective study; Taiwan; adolescent; chronic hepatitis B; complication; drug effect; Hepatitis B virus; liver cell carcinoma; liver tumor; pathology; prognosis; risk factor; virology; young adult; Adolescent; Adult; Aristolochic Acids; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prognosis; Risk Factors; Taiwan; Young Adult |
顯示於: | 環境與職業健康科學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。